Racial impact of secondary metastasis in patients with lung cancer: Evidence of US hospitals in 2020.

Authors

null

Thanathip Suenghataiphorn

Griffin Hospital, Derby, CT

Thanathip Suenghataiphorn , Narathorn Kulthamrongsri , Sakditad Saowapa , Piengpitch Naunsilp , Nutchapon Xanthavanij , Soravis Alm Osataphan

Organizations

Griffin Hospital, Derby, CT, Mayo Clinic, Pheonix, AZ, Texas Tech University Health Sciences Center, Lubbock, TX, Faculty of Medicine Khon Kaen University, Khon Kaen, Thailand, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, Beth Israel Deaconess Medical Center, Boston, MA

Research Funding

No funding sources reported

Background: Lung cancer patient often encounter disparities in health outcomes, especially in difference racial and ethnic groups. Metastasis is the primary cause of cancer morbidity and mortality. However, data on the metastasis risks and clinical outcomes on hospitalized individuals with lung cancer is still limited. Therefore, we aim to assess the association between metastatic lung cancer and racial differences. Methods: We analyzed the 2020 U.S. National Inpatient Sample (NIS) to explore patients who have lung cancer as the primary diagnosis. Additionally, we identified evidence of metastasis, as recorded by ICD-10-CM. Adjusted odds ratios (aORs) for specified outcomes were calculated through multivariable logistic and linear regression analyses. The primary outcome was racial differences in organ metastasis and secondary outcomes included mortality and length of stay. Statistical significance was established at p-value of 0.05. Results: We identified 103,335 patients with primary diagnosis of lung and bronchus cancer at discharge. The mean age was 68.9 years; 50.5% were female. Caucasians accounted for 74.3%, with African Americans at 12.1% and Hispanics at 4.6%. 10% of the patients had brain metastasis, whereas 14% had bone metastasis. In a multivariate analysis adjusting for patient, COVID-19, chemotherapy usage and hospital factors, African Americans had higher risk of brain metastasis (aOR 1.18; 95%CI (1.02, 1.37), p = 0.002), higher risk of bone metastasis (aOR 1.16; 95%CI (1.02, 1.33), p = 0.025), higher risk of mortality (aOR 1.21; 95% CI (1.01, 1.45), p = 0.039) and longer length of stay (b = 0.85; 95%CI (0.55, 1.16), p = 0.001). Hispanics also had higher risk of brain (aOR 1.36, p < 0.05) and prolonged length of stay (b 0.79, p < 0.005). We observed an increase in risk of metastasis and mortality but non-statistically significant in some parameters and races, as shown in table provided. Conclusions: In conclusion, our study revealed that racial difference is associated with higher risk of metastasis, as well as other outcomes. Further longitudinal research is necessary to establish a causal relationship between races, metastasis, and mortality in patients with lung cancer.

Adjusted odds ratio, adjusted for patient characteristics, hospital location and COVID-19 conditions.

RaceBrain MetastasisBone MetastasisMortalityLength of Stay**
African American1.18 (1.02, 1.37)*1.16 (1.02, 1.33)*1.21 (1.01, 1.45)*0.85 (0.55, 1.16)*
Hispanic1.36 (1.12, 1.66)*1.21 (0.99, 1.49)1.11 (0.83, 1.48)0.79 (0.28, 1.31)*
Asian0.96 (0.74, 1.24)1.26 (1.01, 1.57)*1.17 (0.86, 1.60)0.20 (-0.28, 0.69)
Native American1.59 (0.88, 2.85)1.40 (0.80, 2.43)2.02 (0.98, 4.16)0.13 (-1.10, 1.37)
Others1.04 (0.77, 1.42)1.08 (0.80, 1.44)1.05 (0.66, 1.67)0.46 (-0.12, 1.06)

*Denotes statistically significant at p-level < 0.05.

**Length of Stay is expressed as beta-coefficient.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2024 ASCO Breakthrough

Session Type

Poster Session

Session Title

Poster Session B

Track

Thoracic Cancers,Breast Cancer,Gynecologic Cancer,Head and Neck Cancer,Hematologic Malignancies,Genetics/Genomics/Multiomics,Healthtech Innovations,Models of Care and Care Delivery,Viral-Mediated Malignancies,Other Malignancies or Topics

Sub Track

Real-World Evidence/Real-World Data

Citation

J Clin Oncol 42, 2024 (suppl 23; abstr 213)

DOI

10.1200/JCO.2024.42.23_suppl.213

Abstract #

213

Poster Bd #

K8

Abstract Disclosures

Similar Abstracts

Abstract

2022 ASCO Annual Meeting

Sociodemographic trends in COVID-19 mortality in patients with cancer: A nationwide analysis.

First Author: Sree Jambunathan

Abstract

2023 ASCO Annual Meeting

Risk of death among lung cancer patients before and during the COVID-19 pandemic.

First Author: Teddy Tai Loy Lee